Inflammation is an essential protective response of the body — but chronic low-grade inflammation is at the centre of research into cardiovascular disease, type 2 diabetes, rheumatism and other conditions. Omega-3 fatty acids, in particular EPA (eicosapentaenoic acid) and DHA (docosahexaenoic acid), have been intensively investigated for their anti-inflammatory properties for decades. An umbrella meta-analysis from 2022, which pooled 32 existing meta-analyses, showed a statistically significant reduction in the three most important inflammatory markers — CRP, TNF-alpha and IL-6.
On this page you will find how the mechanisms of action work at the molecular level, what the scientific evidence shows, and what this means for practical supplementation.
TL;DR — Key points at a glance
- An umbrella meta-analysis (Gao 2022) of 32 individual analyses showed that EPA+DHA significantly reduces CRP (ES = −0.40), TNF-alpha (ES = −0.23) and IL-6 (ES = −0.22).
- EPA and DHA act through at least 4 mechanisms: displacement of arachidonic acid, NF-kappaB inhibition, PPAR-gamma activation and formation of resolvins/protectins.
- Resolvins (formed from EPA) actively resolve inflammation — rather than simply inhibiting it like ibuprofen or corticosteroids.
- Most positive studies used 1–3 g EPA+DHA per day; first effects on CRP appear after 4–8 weeks.
What are inflammatory markers — and why do they matter?
Inflammatory markers are molecules produced in greater quantities by the body during inflammatory processes. Three parameters are primarily used in clinical research:
C-reactive protein (CRP)
CRP is produced in the liver and is one of the most sensitive markers for systemic inflammation. Elevated CRP levels have been epidemiologically associated with cardiovascular disease, metabolic disorders and chronic inflammatory conditions. In clinical practice, the high-sensitivity CRP (hsCRP) value is particularly used for risk assessment.
Tumour necrosis factor alpha (TNF-alpha)
TNF-alpha is a cytokine secreted mainly by macrophages and other immune cells. It plays a central role in coordinating inflammatory reactions and is chronically elevated in conditions such as rheumatoid arthritis, Crohn's disease and psoriasis. Biologic drugs that block TNF-alpha are among the most widely used medicines in autoimmune diseases.
Interleukin-6 (IL-6)
IL-6 is a signalling protein that performs both pro-inflammatory and anti-inflammatory functions. It stimulates the liver to produce CRP and activates immune cells. Chronically elevated IL-6 levels have been associated with insulin resistance, cardiovascular disease and cognitive changes.
Important: not all inflammation is the same
Acute inflammation — for example after injury or infection — is useful and essential to life. The problematic kind is chronic low-grade inflammation ("silent inflammation"), in which inflammatory markers are permanently slightly elevated without an identifiable acute cause. This is precisely where omega-3 research is focused.
Scientific evidence: what does the research show?
The evidence on omega-3 and inflammatory markers is one of the most thoroughly researched areas in nutritional medicine. Of particular relevance is an umbrella meta-analysis from 2022, which for the first time pooled all available meta-analyses on this topic.
Gao et al.: 32 meta-analyses — CRP, TNF-alpha and IL-6 significantly reduced
The umbrella meta-analysis by Gao et al. (2022) pooled 32 prior meta-analyses on omega-3 and inflammatory markers — one of the most comprehensive analyses of this kind. Results: omega-3 supplementation produced a significant reduction in CRP (effect size ES = −0.40; P < 0.001), TNF-alpha (ES = −0.23; P = 0.002) and IL-6 (ES = −0.22; P = 0.010). All three effects were statistically highly significant.
An effect size of −0.40 for CRP corresponds to a moderate effect by Cohen's classification — for a dietary component without pharmacological active substance concentration, this is a considerable value. The reduction in TNF-alpha and IL-6 with ES = −0.22 and −0.23 fell in the small-to-moderate range, but was also statistically robust.
Calder PC: Fatty acid composition, PPAR-gamma and lipid-mediated resolution
In his widely cited mechanistic review, Philip Calder summarised how EPA and DHA act at the cellular level: by modifying the fatty acid composition of the cell membrane, activating the transcription factor PPAR-gamma (which inhibits pro-inflammatory genes), and by forming anti-inflammatory and pro-resolving lipid mediators — including resolvins and protectins.
Mechanisms of action: how do EPA and DHA act at the molecular level?
The anti-inflammatory action of omega-3 fatty acids is not due to a single mechanism, but to the interplay of several molecular processes:
1. Modification of cell membrane composition
Every cell in the human body is surrounded by a lipid bilayer. The fatty acid composition of this membrane largely determines how the cell responds to signals. In a typically Western dietary pattern with high omega-6 content (mainly linoleic acid from vegetable oils), the membrane is rich in arachidonic acid — the precursor of pro-inflammatory eicosanoids (prostaglandins, thromboxanes, leukotrienes of series 2 and 4).
EPA and DHA are incorporated into the membrane and displace arachidonic acid. The result: fewer pro-inflammatory signalling molecules are formed.
2. Inhibition of NF-kappaB
NF-kappaB (nuclear factor kappa-light-chain-enhancer of activated B cells) is a central transcription factor that controls the expression of hundreds of pro-inflammatory genes — including genes for TNF-alpha, IL-6 and COX-2.
EPA and DHA inhibit NF-kappaB activation in multiple ways, including by activating PPAR-gamma, which acts as an antagonist to NF-kappaB. This mechanism is well documented in cell culture and animal studies.
3. Activation of PPAR-gamma
PPAR-gamma (peroxisome proliferator-activated receptor gamma) is a nuclear receptor that is activated after binding of EPA or DHA. It controls the expression of genes that dampen inflammatory reactions, regulate lipid metabolism and influence insulin sensitivity. PPAR-gamma activation by omega-3 is considered one of the most important mechanisms for anti-inflammatory action.
4. Formation of resolvins and protectins
Resolvins and protectins (also called neuroprotectins) are a class of so-called specialised pro-resolving lipid mediators (SPMs), formed directly from EPA and DHA. Unlike classical anti-inflammatory agents (such as corticosteroids or NSAIDs), which primarily inhibit inflammation, resolvins and protectins actively promote the resolution of inflammation — they actively clear it.
They promote the apoptosis of exhausted neutrophils, stimulate macrophages for phagocytosis of cellular debris, and inhibit further migration of inflammatory cells.
Resolvins: the difference from mere inhibition
Classical anti-inflammatory drugs passively suppress inflammatory processes. Resolvins and protectins — formed from EPA and DHA — instead actively activate the body's own resolution programme. This difference is pharmacologically significant: active resolution of inflammation does not lead to immunosuppression, but restores normal homeostasis.
Summary: inflammatory markers and measured effects
| Marker | Function | Effect size (Gao 2022) | Significance |
|---|---|---|---|
| CRP | Acute-phase protein, liver, cardiovascular risk | ES = −0.40 | P < 0.001 |
| TNF-alpha | Macrophage cytokine, tissue inflammation, autoimmunity | ES = −0.23 | P = 0.002 |
| IL-6 | Pleiotropic cytokine, CRP induction, insulin resistance | ES = −0.22 | P = 0.010 |
| Arachidonic acid (AA) | Membrane precursor of pro-inflammatory eicosanoids | Displaced by EPA/DHA | Mechanistically demonstrated |
| NF-kappaB | Transcription factor for pro-inflammatory genes | Inhibited by EPA/DHA | In vitro + animal studies |
| Resolvins/Protectins | Pro-resolving mediators, formed from EPA/DHA | Promotes inflammation resolution | Mechanistically demonstrated |
Omega-6/omega-3 ratio: why balance matters
The anti-inflammatory action of omega-3 cannot be considered in isolation from dietary omega-6 content. EPA and arachidonic acid (the most important omega-6 fatty acid) compete for the same enzymes — cyclooxygenase (COX) and lipoxygenase (LOX).
Eicosanoids formed from EPA (series 3) are less pro-inflammatory than eicosanoids formed from arachidonic acid (series 2). In a typically Western diet, the ratio of omega-6 to omega-3 is often 15:1 to 20:1 — far from the evolutionarily estimated ratio of approximately 4:1 to 1:1. A higher omega-3 intake improves this ratio in favour of EPA and DHA, directly influencing eicosanoid synthesis.
More information on this topic can be found on the page Omega-3 vs omega-6: the right ratio.
What doses were studied?
Doses used in inflammation studies vary considerably. Most positive effects on CRP were observed with doses of 1–3 g EPA+DHA per day. Some studies showed CRP reduction even with lower doses (500–1,000 mg/day), particularly in people with elevated baseline values.
Important: product quality plays a role. A fish oil with 30% EPA+DHA content provides only 900 mg of active fatty acids from 3 g of capsule content. Highly concentrated products with 70–80% EPA+DHA reach the same amount of active substance with far fewer capsules.
EFSA health claims on inflammation
The European Food Safety Authority (EFSA) has not approved any specific health claim for "anti-inflammatory" effects of omega-3 — as this would constitute a therapeutic claim. Approved EFSA claims relate to heart function (250 mg EPA+DHA/day), brain and visual function (250 mg DHA/day), blood pressure (3,000 mg/day) and triglycerides (2,000 mg/day). The anti-inflammatory research is nevertheless scientifically very robust — it simply cannot be communicated as a health claim on packaging.
Which population groups were studied?
Meta-analyses on anti-inflammatory action cover a broad spectrum of participants: healthy adults with slightly elevated inflammatory markers, rheumatoid arthritis patients, people with metabolic syndrome, type 2 diabetics, overweight individuals and older adults. Effects on CRP tended to be more pronounced in populations with elevated baseline values than in healthy normal populations — corresponding to the general principle of supplementation interventions.
Particularly well studied: metabolic syndrome
In people with metabolic syndrome — a cluster of abdominal obesity, elevated triglycerides, low HDL cholesterol, elevated blood pressure and fasting blood glucose — chronic inflammation markers are typically elevated. Several studies show that omega-3 supplementation can have particularly pronounced effects on CRP and IL-6 in this group.
Older adults
With ageing, systemic inflammatory markers tend to increase — a phenomenon known as "inflammaging". Studies suggest that omega-3 can also act anti-inflammatorily in older people, with effect sizes comparable to younger populations.
Comparison with other anti-inflammatory interventions
Omega-3 fatty acids are not medicines and are not a substitute for pharmacological therapies for inflammatory diseases. Comparison with other lifestyle interventions is, however, informative:
| Intervention | CRP reduction (meta-analysis) | Quality of evidence |
|---|---|---|
| Omega-3 (EPA+DHA) | ES = −0.40 (Gao 2022) | Very high (umbrella meta-analysis) |
| Moderate aerobic exercise | Moderate CRP reduction | Well documented |
| Weight loss | Notable CRP reduction in obesity | Well documented |
| Mediterranean diet | Moderate reduction | Well documented |
| Curcumin | Variable effects, small to moderate | Moderate (bioavailability problem) |
Practical assessment: what does this mean for you?
The available research consistently shows that EPA and DHA can statistically significantly reduce inflammatory markers. The clinical relevance of these effects depends on context: in healthy people with normal values, absolute changes are small. In people with chronically elevated inflammatory markers — for example in rheumatism, metabolic syndrome or after intensive training — the effects can be clinically significant.
Omega-3 is not a therapeutic intervention, but a dietary component that can be used as part of a balanced diet and healthy lifestyle. The anti-inflammatory action of EPA is particularly relevant for recovery after sport: intensive training produces micro-inflammation in muscles, and its rapid resolution influences recovery and performance.
If you have an inflammatory condition, always consult your doctor before taking omega-3 supplements — especially in combination with anticoagulants.
More information on specific inflammatory conditions can be found on the pages Omega-3 for rheumatism and arthritis and Omega-3 and the immune system. The molecular background of EPA is explained on the page EPA: eicosapentaenoic acid — action and sources.
Frequently asked questions
Can omega-3 cure inflammation?
No. Omega-3 fatty acids are not medicines and do not replace medical treatment. Studies show that EPA and DHA can significantly reduce inflammatory markers such as CRP, TNF-alpha and IL-6 — but this does not mean curing inflammatory diseases. In conditions such as rheumatoid arthritis, omega-3 can be used as a complementary measure alongside drug therapy.
How long does omega-3 take to influence inflammatory markers?
Studies show that the first measurable changes in CRP can appear after 4–8 weeks. Full effects are generally observed after 3–6 months. The incorporation of EPA and DHA into cell membranes — which underlies the mechanism of action — takes several weeks. Short-term use over a few days shows no relevant effects on inflammatory markers.
What doses were used in inflammation studies?
Most studies showing positive effects on inflammatory markers used doses of 1–3 g EPA+DHA per day. What matters is the quantity of active fatty acids (EPA+DHA), not the total amount of fish oil. A product with 1,000 mg total content per capsule can contain very different amounts of EPA+DHA — from 300 mg to over 800 mg — depending on concentration.
What is the difference between resolvins and classical anti-inflammatories?
Classical anti-inflammatory drugs such as NSAIDs (e.g. ibuprofen) or corticosteroids passively inhibit inflammatory processes — they suppress the inflammatory cascade. Resolvins, formed from EPA, act pro-resolutively: they actively activate the body's own resolution programme, stimulating macrophages for phagocytosis and guiding exhausted neutrophils towards apoptosis. This restores tissue homeostasis without suppressing immune function.
Is fish oil or algae oil better for anti-inflammatory action?
Both sources provide EPA and DHA — the relevant fatty acids for anti-inflammatory action. Algae oil is the vegan alternative and primarily contains DHA; some algae oils are now also rich in EPA. Fish oil contains both fatty acids in variable ratios. For reducing inflammatory markers, EPA is especially important according to study evidence; DHA also has anti-inflammatory properties, but the data for DHA alone are less consistent than for EPA. For immunomodulation and resolvins, EPA is the more important fatty acid.
Interaction with anticoagulants
Omega-3 fatty acids have a mild antiplatelet effect. If you take anticoagulant medications such as warfarin, heparin or high-dose aspirin, omega-3 supplementation at doses above 3 g/day should be coordinated with your doctor. Below 2 g/day, the risk of clinically relevant interactions is low according to current data.
Medical disclaimer
This article is for general information purposes only and does not replace medical advice. All health statements are based on EFSA-authorised health claims and published studies. Omega-3 supplements are food supplements and are not a substitute for a balanced diet or medical treatment. In the event of existing conditions or medication use, always consult a doctor.
This article is part of our health overview — there you will find all other areas of action for omega-3, from cardiovascular health and brain function to specific clinical conditions. What to look for when buying a high-EPA supplement is explained in the quality overview.